<DOC>
	<DOCNO>NCT01165385</DOCNO>
	<brief_summary>The aim research evaluate potential interest association Pazopanib , multi-tyrosine kinase inhibitor , cisplatin . As cisplatin marketing approval several cancer ( ovarian , testicle , bladder , esophagus , endometrium , lung , stomach , head neck cancer ( HNC ) ) , order rapid evaluation combination , evaluate combination patient whose tumor know sensible cisplatin ( except tumor risk bleed ) . This study classical phase 1 trial pazopanib 3-weekly cisplatin association . It allow optimal dose selection pharmacokinetic analysis . It plan include around 38 patient , enrich optimal tolerate regimen ( OTR ) level cohort triple negative breast cancer patient . If association proven feasible , move specific phase II study triple negative breast cancer patient .</brief_summary>
	<brief_title>Study With Pazopanib Combination With Cisplatin ( CDDP ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The main objective study determine dose limit toxicity ( DLT ) optimal tolerate regimen ( OTR ) safety criterion evaluate upon NCI CTC-AE system version 4.0 . Efficacy primary objective ; however anti-tumor activity pazopanib/cisplatin combination carry determination objective response rate accord RECIST criterion version 1.1 . The objective response define either complete response ( CR ) partial response ( PR ) , assess either CT Scan and/or MRI and/or bone Scan , perform baseline every 6 week . This open-label , non-randomized , dose escalation pharmacokinetic , phase I study pazopanib cisplatin patient relapse refractory solid tumor ( except tumor risk bleed ) select combined chemotherapy indicate reasonable option ( per tumor characteristic previous treatment ) . All eligible patient enter study receive daily oral pazopanib , supply 200 mg aqueous film-coated tablet intravenous cisplatin every three week . Doses compound adjusted accord reach dose level . The treatment continue development unacceptable toxicity evidence disease progression patient 's / investigator 's decision withdrawal . All patient receive least dose study drug follow survival outcome .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Main Documented metastatic solid malignancy patient candidate receive cisplatin base regimen . During dose seek procedure : ALL solid tumor During Optimal Tolerated Regimen validation procedure : ONLY HER2RH breast cancer Measurable evaluable disease WHO performance status ≤ 1 Negative dipstick proteinuria test positive proteinuria &lt; 1g/24h . If proteinuria appear ≥ 2+ routine dipstick testing , patient must undergo 24H urine collection demonstrate proteinuria &lt; 1g/24H Corrected QT interval ( QTc ) ≤ 480 msec use Bazett 's formula Main Prior treatment cisplatin reach cumulative dose &gt; 300 mg/m2 HER2 positive breast cancer Patients high risk bleed Clinically significant gastrointestinal abnormality may affect absorption investigational product calcium magnesium level inferior standard level ( measure within 14 day first pazopanib dose ) potassium level inferior standard level ( measure within 72 hour first pazopanib dose ) Patients concurrent severe and/or uncontrolled medical disease could compromise participation study Hearing impairment/tinnitus &gt; = grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Relapsed refractory solid tumor</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Cisplatin</keyword>
</DOC>